Sanavia Oncology Inc.
- Biotech or pharma, therapeutic R&D
PRESENTING ON WEDNESDAY JUNE 18 AT 10:00AM IN ROOM 153A
New targets and epitopes to bind, more ways to fight, more patients to help.
Sanavia Oncology Inc. is a New York-based biotech company with a founding team from Rockefeller University, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Columbia University, Amgen, Genentech, Roche and Gilead. Sanavia’s pioneering epitope discovery technology identifies novel cancer-specific epitopes in validated cancer targets that are present in majority of patients across multiple cancer types and selects the best epitope for ADC, CAR-T or T cell engagers (TCEs). Sanavia combines antibody screening technology with Machine Learning and AI to pick the best functionally and structurally optimized ADC, CAR-T or TCEs that bind to their epitopes with atomic precision and work in vivo. SANA-01 program targets a novel epitope present in 75% of lung, 70% of TNBC, 70% of ovarian, 40% of colon, 75% of pancreatic, and 55% of gastric cancers.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}